MetMAb Match Play

The increase in overall survival in a Phase II trial of MetMab was tiny, but the combination of a near-doubling of progression-free survival, a promising hazard ratio, and a companion diagnostic to find the right patients in non-small cell lung cancer explains why Roche and its Genentech Inc. unit have high hopes for the molecule.

Preliminary Phase II data were presented at the European Society for Medical Oncology meeting for both MetMAb and a companion biomarker to target therapy to responders. The companies are now discussing Phase III designs with regulators...